Handelen Aytu BioScience, Inc. - AYTU CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | 0.134 | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.025457% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.003235% | ||||||||
| Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 0.01 | ||||||||
| Valuta | USD | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United States of America | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
Aytu Biopharma Inc ESG Risk Ratings
High Medium Low Negligible
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Belangrijkste statistieken
| Prev. Close* | 1.627 |
| Open* | 1.696 |
| 1-Jaarlijkse Verandering* | 210.62% |
| Dagelijks bereik* | 1.588 - 1.697 |
| 52 wekelijks bereik | 1.40-16.19 |
| Weekgemiddelde volume (10 dagen) | 52.56K |
| Gemiddeld volume (3 maanden) | 1.74M |
| Marktkapitalisatie | 6.35M |
| P/E Ratio | -100.00K |
| Uitstaande Aandelen | 3.78M |
| Omzet | 104.12M |
| EPS | -206.58 |
| Dividend (opbrengst %) | N/A |
| Beta | -0.39 |
| Volgende inkomsten datum | Sep 25, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|---|---|---|---|---|---|
| May 26, 2023 | 1.627 | 0.000 | 0.00% | 1.627 | 1.805 | 1.617 |
| May 25, 2023 | 1.618 | -0.147 | -8.33% | 1.765 | 1.766 | 1.558 |
| May 24, 2023 | 1.746 | -0.029 | -1.63% | 1.775 | 1.815 | 1.696 |
| May 23, 2023 | 1.765 | -0.009 | -0.51% | 1.774 | 1.904 | 1.765 |
| May 22, 2023 | 1.874 | 0.020 | 1.08% | 1.854 | 1.934 | 1.824 |
| May 19, 2023 | 1.844 | 0.020 | 1.10% | 1.824 | 1.934 | 1.795 |
| May 18, 2023 | 1.835 | 0.020 | 1.10% | 1.815 | 1.854 | 1.775 |
| May 17, 2023 | 1.736 | 0.090 | 5.47% | 1.646 | 1.746 | 1.607 |
| May 16, 2023 | 1.677 | 0.001 | 0.06% | 1.676 | 1.795 | 1.666 |
| May 15, 2023 | 1.726 | 0.011 | 0.64% | 1.715 | 1.805 | 1.697 |
| May 12, 2023 | 1.776 | -0.246 | -12.17% | 2.022 | 2.022 | 1.726 |
| May 11, 2023 | 2.022 | -0.010 | -0.49% | 2.032 | 2.151 | 1.913 |
| May 10, 2023 | 2.002 | 0.060 | 3.09% | 1.942 | 2.092 | 1.804 |
| May 9, 2023 | 1.953 | 0.326 | 20.04% | 1.627 | 2.052 | 1.577 |
| May 8, 2023 | 1.667 | 0.208 | 14.26% | 1.459 | 1.697 | 1.459 |
| May 5, 2023 | 1.480 | 0.041 | 2.85% | 1.439 | 1.519 | 1.341 |
| May 4, 2023 | 1.529 | -0.079 | -4.91% | 1.608 | 1.618 | 1.470 |
| May 3, 2023 | 1.608 | 0.020 | 1.26% | 1.588 | 1.628 | 1.568 |
| May 2, 2023 | 1.588 | -0.098 | -5.81% | 1.686 | 1.736 | 1.578 |
| May 1, 2023 | 2.219 | 0.010 | 0.45% | 2.209 | 2.250 | 2.209 |
Aytu BioScience, Inc. Events
| Tijd (UTC) (UTC) | Land | Evenement |
|---|---|---|
| Monday, September 25, 2023 | ||
| Tijd (UTC) (UTC) 20:00 | Land US
| Evenement Q4 2023 Aytu Biopharma Inc Earnings Release Q4 2023 Aytu Biopharma Inc Earnings ReleaseForecast -Previous - |
| Monday, November 13, 2023 | ||
| Tijd (UTC) (UTC) 21:00 | Land US
| Evenement Q1 2024 Aytu Biopharma Inc Earnings Release Q1 2024 Aytu Biopharma Inc Earnings ReleaseForecast -Previous - |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totale inkomsten | 96.669 | 65.632 | 27.6321 | 7.32036 | 3.66012 |
| Inkomsten | 96.669 | 65.632 | 27.6321 | 7.32036 | 3.66012 |
| Kosten van opbrengsten, totaal | 44.386 | 36.432 | 7.55303 | 2.20204 | 2.05054 |
| Brutowinst | 52.283 | 29.2 | 20.0791 | 5.11832 | 1.60958 |
| Totale bedrijfskosten | 208.061 | 126.071 | 38.6481 | 33.9975 | 17.0825 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 69.88 | 55.808 | 34.8024 | 19.2396 | 17.7325 |
| Onderzoek & Ontwikkeling | 14.439 | 5.623 | 1.72142 | 0.58907 | 0.1676 |
| Depreciation / Amortization | 4.067 | 6.009 | 4.49047 | 2.13626 | 1.55371 |
| Ongebruikelijke uitgaven (inkomsten) | 75.289 | 22.199 | -9.91925 | 9.83055 | -4.42185 |
| Bedrijfsresultaat | -111.392 | -60.439 | -11.016 | -26.6772 | -13.4224 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -0.862 | -2.05 | -2.60466 | -0.45472 | 3.2345 |
| Netto inkomen voor belastingen | -110.283 | -58.03 | -13.6207 | -27.1319 | -10.1879 |
| Netto inkomen na belastingen | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Netto inkomen voor extra. Posten | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Netto inkomen | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Verwaterd Netto Inkomen | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Verwaterd Gewogen Gemiddelde Aandelen | 0.07349 | 0.83733 | 0.22596 | 0.03897 | 0.00333 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -1499.08 | -69.6126 | -60.2791 | -696.182 | -3061.23 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Verwaterde Genormaliseerde Winst per Aandeel | -833.202 | -52.3801 | -104.177 | -443.938 | -4389.91 |
| Totale buitengewone posten | 0 | ||||
| Overige, Netto | 1.971 | 4.459 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totale inkomsten | 22.733 | 26.279 | 27.655 | 27.448 | 24.199 |
| Inkomsten | 22.733 | 26.279 | 27.655 | 27.448 | 24.199 |
| Kosten van opbrengsten, totaal | 9.99 | 8.986 | 9.623 | 12.606 | 11.513 |
| Brutowinst | 12.743 | 17.293 | 18.032 | 14.842 | 12.686 |
| Totale bedrijfskosten | 31.291 | 33.072 | 29.308 | 45.361 | 78.685 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 19.981 | 18.578 | 17.424 | 17.396 | 17.358 |
| Onderzoek & Ontwikkeling | 0.856 | 1.71 | 1.064 | 3.697 | 3.726 |
| Depreciation / Amortization | 1.198 | 1.198 | 1.197 | 0.853 | 1.061 |
| Ongebruikelijke uitgaven (inkomsten) | 0 | 2.6 | 10.809 | 45.027 | |
| Bedrijfsresultaat | -8.558 | -6.793 | -1.653 | -17.913 | -54.486 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | 1.358 | 0.1 | 1.08 | -0.787 | -0.055 |
| Overige, Netto | -0.128 | 0.999 | 1.468 | ||
| Netto inkomen voor belastingen | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Netto inkomen na belastingen | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Netto inkomen voor extra. Posten | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Netto inkomen | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Verwaterd Netto Inkomen | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Verwaterd Gewogen Gemiddelde Aandelen | 3.72678 | 3.1103 | 0.1259 | 0.08989 | 1.48449 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -1.93196 | -2.15188 | -5.56812 | -196.925 | -35.7516 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Verwaterde Genormaliseerde Winst per Aandeel | -1.93196 | -1.31595 | -5.56812 | -76.6739 | -5.42003 |
| Other Operating Expenses, Total | -0.734 |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 59.929 | 105.234 | 75.4226 | 15.4329 | 9.47029 |
| Geldmiddelen en kortetermijnbeleggingen | 19.36 | 49.649 | 48.0817 | 11.0442 | 7.01253 |
| Geldmiddelen & Equivalenten | 19.36 | 49.649 | 48.0817 | 11.0442 | 7.01253 |
| Korte Termijn Investeringen | |||||
| Totale Vorderingen, Netto | 21.712 | 28.176 | 5.63272 | 1.74079 | 0.57878 |
| Accounts Receivable - Trade, Net | 21.712 | 28.176 | 5.63272 | 1.74079 | 0.57878 |
| Total Inventory | 10.849 | 16.339 | 9.99944 | 1.44007 | 1.33897 |
| Prepaid Expenses | 7.375 | 9.78 | 5.71509 | 0.95778 | 0.44001 |
| Total Assets | 137.623 | 265.668 | 153.293 | 34.7214 | 21.0601 |
| Property/Plant/Equipment, Total - Net | 6.296 | 8.703 | 0.89261 | 0.20373 | 0.21868 |
| Goodwill, Net | 0 | 65.802 | 28.0904 | 0 | |
| Intangibles, Net | 70.632 | 85.464 | 48.8546 | 19.0826 | 11.366 |
| Other Long Term Assets, Total | 0.766 | 0.465 | 0.03298 | 0.0022 | 0.00509 |
| Total Current Liabilities | 64.442 | 109.438 | 28.7634 | 5.37258 | 3.39478 |
| Payable/Accrued | 9.468 | 8.689 | 0.959 | ||
| Accrued Expenses | 35.946 | 49.485 | 11.1046 | 1.99724 | 0.72656 |
| Notes Payable/Short Term Debt | 3.813 | 7.934 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 4.132 | 7.407 | 4.87523 | 1.07807 | 0.54855 |
| Total Liabilities | 91.531 | 128.1 | 58.2778 | 27.6336 | 7.63559 |
| Total Long Term Debt | 14.279 | 0.18 | 0 | 0 | 0 |
| Other Liabilities, Total | 12.81 | 18.482 | 29.5145 | 22.261 | 4.24081 |
| Total Equity | 46.092 | 137.568 | 95.0153 | 7.08782 | 13.4245 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0.00036 | 0 |
| Common Stock | 0.004 | 0.003 | 0.00126 | 0.00175 | 0.00018 |
| Additional Paid-In Capital | 334.56 | 315.864 | 215.024 | 113.475 | 92.6819 |
| Retained Earnings (Accumulated Deficit) | -288.472 | -178.299 | -120.01 | -106.39 | -79.2576 |
| Total Liabilities & Shareholders’ Equity | 137.623 | 265.668 | 153.293 | 34.7214 | 21.0601 |
| Total Common Shares Outstanding | 1.92894 | 1.37452 | 0.62919 | 0.08769 | 0.00897 |
| Other Current Assets, Total | 0.633 | 1.29 | 5.9936 | 0.25 | 0.1 |
| Accounts Payable | 10.987 | 19.255 | 11.8246 | 2.29727 | 2.11967 |
| Property/Plant/Equipment, Total - Gross | 8.717 | 9.715 | 1.37661 | 0.59973 | 0.75868 |
| Accumulated Depreciation, Total | -2.421 | -1.012 | -0.484 | -0.396 | -0.54 |
| Total Preferred Shares Outstanding | 0 | 0 | 3.59498 | ||
| Current Port. of LT Debt/Capital Leases | 0.096 | 16.668 | 0 | ||
| Capital Lease Obligations | 0.084 | 0.18 | 0 | ||
| Long Term Debt | 14.195 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 78.465 | 70.611 | 74.415 | 59.929 | 77.947 |
| Geldmiddelen en kortetermijnbeleggingen | 19.179 | 19.501 | 23.811 | 19.36 | 27.613 |
| Geldmiddelen & Equivalenten | 19.179 | 19.501 | 23.811 | 19.36 | 27.613 |
| Totale Vorderingen, Netto | 34.043 | 25.547 | 27.924 | 21.712 | 27.613 |
| Accounts Receivable - Trade, Net | 34.043 | 25.547 | 27.924 | 21.712 | 27.613 |
| Total Inventory | 13.637 | 12.95 | 12.871 | 10.849 | 13.891 |
| Prepaid Expenses | 10.429 | 11.989 | 9.024 | 7.375 | 7.942 |
| Other Current Assets, Total | 1.177 | 0.624 | 0.785 | 0.633 | 0.888 |
| Total Assets | 147.216 | 141.436 | 150 | 137.623 | 168.826 |
| Property/Plant/Equipment, Total - Net | 4.395 | 5.019 | 5.648 | 6.296 | 7.04 |
| Property/Plant/Equipment, Total - Gross | 7.779 | 8.083 | 8.384 | 8.717 | 8.78 |
| Accumulated Depreciation, Total | -3.384 | -3.064 | -2.736 | -2.421 | -1.74 |
| Goodwill, Net | 0 | 8.637 | |||
| Intangibles, Net | 63.464 | 64.985 | 69.108 | 70.632 | 74.428 |
| Other Long Term Assets, Total | 0.892 | 0.821 | 0.829 | 0.766 | 0.774 |
| Total Current Liabilities | 85.416 | 67.15 | 73.204 | 64.442 | 80.36 |
| Accounts Payable | 14.673 | 10.58 | 14.667 | 10.987 | 11.13 |
| Payable/Accrued | 10.287 | 9.137 | 8.08 | 9.468 | 12.058 |
| Accrued Expenses | 40.55 | 33.326 | 34.603 | 35.946 | 47.873 |
| Notes Payable/Short Term Debt | 10.403 | 7.429 | 8.087 | 3.813 | 3.385 |
| Current Port. of LT Debt/Capital Leases | 3.305 | 0.09 | 0.925 | 0.096 | 0.1 |
| Other Current Liabilities, Total | 6.198 | 6.588 | 6.842 | 4.132 | 5.814 |
| Total Liabilities | 106.304 | 95.619 | 96.094 | 91.531 | 107.682 |
| Total Long Term Debt | 11.386 | 14.533 | 13.56 | 14.279 | 14.167 |
| Long Term Debt | 11.371 | 14.494 | 13.498 | 14.195 | 14.061 |
| Capital Lease Obligations | 0.015 | 0.039 | 0.062 | 0.084 | 0.106 |
| Other Liabilities, Total | 9.502 | 13.936 | 9.33 | 12.81 | 13.155 |
| Total Equity | 40.912 | 45.817 | 53.906 | 46.092 | 61.144 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.00038 | 0.00034 | 0.006 | 0.004 | 0.003 |
| Additional Paid-In Capital | 342.584 | 340.289 | 345.253 | 334.56 | 331.912 |
| Retained Earnings (Accumulated Deficit) | -301.672 | -294.472 | -291.353 | -288.472 | -270.771 |
| Total Liabilities & Shareholders’ Equity | 147.216 | 141.436 | 150 | 137.623 | 168.826 |
| Total Common Shares Outstanding | 3.77951 | 3.38315 | 3.12147 | 1.92894 | 1.6678 |
| Total Preferred Shares Outstanding | |||||
| Other Equity, Total | -0.00038 | -0.00034 |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netto-inkomen/Beginsaldo | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Geldmiddelen uit Operationele Activiteiten | -28.823 | -25.964 | -28.3739 | -13.8314 | -15.9403 |
| Geldmiddelen uit Operationele Activiteiten | 10.251 | 9.201 | 6.24583 | 2.72707 | 2.59127 |
| Deferred Taxes | |||||
| Niet-Geldelijke Posten | 81.962 | 21.443 | -8.38913 | 10.7837 | -7.62492 |
| Veranderingen in het Operationeel Kapitaal | -10.863 | 1.681 | -12.6099 | -0.2102 | -0.71881 |
| Geldmiddelen uit Investeringsactiviteiten | -3.248 | -2.782 | -5.65577 | -1.06199 | -0.48429 |
| Kapitaaluitgaven | -2.341 | 0 | -0.05985 | -0.07471 | |
| Overige Cash Flow investeringsposten, Totaal | -3.248 | -0.441 | -5.65577 | -1.00214 | -0.40959 |
| Geldmiddelen uit Financieringsactiviteiten | 1.53 | 30.314 | 71.0687 | 19.0751 | 22.6596 |
| Financiering van Cash Flow Posten | -4.942 | -10.996 | -5.40415 | -1.47996 | -2.75752 |
| Uitgifte (Aflossing) van aandelen, netto | 11.694 | 45.051 | 92.7217 | 15.555 | 25.4171 |
| Uitgifte (Aflossing) van Schulden, Netto | -5.222 | -3.741 | -16.2488 | 5 | |
| Nettowijziging in Geldmiddelen | -30.541 | 1.568 | 37.0391 | 4.1817 | 6.23499 |
| Contant Betaalde Rente | 3.148 | 1.249 | 1.04028 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -14.594 | -7.394 | -2.881 | -110.173 | -92.472 |
| Cash From Operating Activities | -14.494 | -11.588 | -9.148 | -28.823 | -21.728 |
| Cash From Operating Activities | 6.699 | 4.505 | 2.328 | 10.251 | 8.005 |
| Non-Cash Items | 1.658 | 3.846 | 1.488 | 81.962 | 67.39 |
| Cash Interest Paid | 2.861 | 2.021 | 0.565 | 3.148 | 3.08 |
| Changes in Working Capital | -8.257 | -12.545 | -10.083 | -10.863 | -4.651 |
| Cash From Investing Activities | 0.038 | 0.037 | 0.042 | -3.248 | -3.207 |
| Other Investing Cash Flow Items, Total | 0.038 | 0.037 | 0.042 | -3.248 | -3.207 |
| Cash From Financing Activities | 14.275 | 11.692 | 13.557 | 1.53 | 2.647 |
| Financing Cash Flow Items | -5.254 | -3.497 | -1.107 | -4.942 | -4.429 |
| Issuance (Retirement) of Stock, Net | 13.012 | 11.573 | 10.416 | 11.694 | 12.7 |
| Issuance (Retirement) of Debt, Net | 6.517 | 3.616 | 4.248 | -5.222 | -5.624 |
| Net Change in Cash | -0.181 | 0.141 | 4.451 | -30.541 | -22.288 |
| Capital Expenditures |
| Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
|---|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | Hedge Fund | 7.1847 | 271595 | 0 | 2023-05-26 | LOW |
| Alyeska Investment Group, L.P. | Hedge Fund | 1.984 | 75000 | 0 | 2023-03-31 | LOW |
| Brooke (Christopher) | Individual Investor | 1.5438 | 58357 | 58357 | 2022-11-15 | |
| Disbrow (Joshua R.) | Individual Investor | 1.5235 | 57591 | -3 | 2023-03-24 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 1.3127 | 49623 | -57416 | 2023-03-31 | HIGH |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1.2503 | 47263 | 4379 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.6365 | 24059 | -1 | 2023-03-31 | LOW |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.5962 | 22537 | 2640 | 2023-03-31 | MED |
| Commonwealth Financial Network | Investment Advisor | 0.4137 | 15637 | 159 | 2023-03-31 | LOW |
| PGIM Quantitative Solutions LLC | Investment Advisor | 0.375 | 14176 | 5198 | 2023-03-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.3185 | 12039 | -2 | 2023-03-31 | LOW |
| Oki (Mark K) | Individual Investor | 0.2513 | 9500 | 0 | 2023-03-24 | LOW |
| Pyszczymuka (Greg) | Individual Investor | 0.2408 | 9103 | 5000 | 2022-12-19 | |
| Cantrell (Gary V.) | Individual Investor | 0.217 | 8204 | -2000 | 2022-12-21 | |
| Dockery (Carl C) | Individual Investor | 0.2157 | 8152 | -2 | 2023-03-24 | LOW |
| Liu (Vivian H) | Individual Investor | 0.1805 | 6825 | 0 | 2023-03-24 | HIGH |
| Ronald Blue Trust, Inc. | Investment Advisor | 0.1476 | 5579 | 5300 | 2023-03-31 | LOW |
| UBS Financial Services, Inc. | Investment Advisor | 0.1395 | 5273 | 5012 | 2023-03-31 | LOW |
| Tower Research Capital LLC | Hedge Fund | 0.0457 | 1726 | 113 | 2023-03-31 | HIGH |
| Morgan Stanley & Co. LLC | Research Firm | 0.0228 | 861 | 0 | 2023-03-31 | MED |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group530K+
Handelaren
87K+
Actieve klanten per maand
$46M+
Maandelijks beleggingsvolume
$31M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
Handelscommissie
0
- 1:1
Hefboom
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
Aytu BioScience, Inc. Company profile
Over Aytu BioScience, Inc.
Aytu Biopharma, Inc, voorheen Aytu BioScience, Inc, is een gespecialiseerd farmaceutisch bedrijf. Het bedrijf brengt een portefeuille van op recept verkrijgbare producten op de markt voor eerstelijnszorg en de pediatrische markt. De producten op recept van het bedrijf behandelen voornamelijk aandachtstekortstoornis met hyperactiviteit (ADHD) en andere veel voorkomende pediatrische aandoeningen. Het bedrijf verkoopt de ADHD-producten Adzenys XR-ODT (amfetamine) tabletten met verlengde afgifte, Cotempla XR-ODT (methylfenidaat) tabletten met verlengde afgifte, en Adzenys-ER (amfetamine) suspensie voor oraal gebruik met verlengde afgifte. Andere pediatrische producten van de Vennootschap zijn Karbinal ER (carbinoxaminemaleaat), een suspensie met verlengde afgifte van carbinoxamine (antihistamine) voor de behandeling van talrijke allergische aandoeningen, en Poly-Vi-Flor en Tri-Vi-Flor, twee complementaire op fluoride gebaseerde vitamineproducten op recept die combinaties van fluoride en vitaminen bevatten in formuleringen voor zuigelingen en kinderen met een tekort aan fluoride.
| Industry: | Pharmaceuticals (NEC) |
373 Inverness Pkwy Ste 206
80112
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 530.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen